Skip to content

Rallybio

  • About Us
    • Company Overview
    • Team
    • Board of Directors
  • Our Science
    • Our Pipeline
    • Our Process
  • Newsroom
  • Investors
  • Contact

Our Mission

To Identify and Accelerate the Development of Life-Transforming Therapies for Patients with Severe and Rare Disorders

Discover How

  • About Us
    • Company Overview
    • Team
    • Board of Directors
  • Our Science
    • Our Pipeline
    • Our Process
  • Newsroom
  • Investors
  • Contact

“Millions of patients with severe and rare disorders still suffer without meaningful treatment options. We are proceeding with an unswerving urgency to identify and advance life-transforming therapeutic candidates for patients in need.”

— Martin Mackay, PhD, Co-Founder

About Rallybio

Rallybio Newsroom

  • January 21, 2021 | Press Releases

    Steven Tuch Joins Rallybio to Lead Corporate Development

  • November 24, 2020 | Press Releases

    Rallybio to Present at the 3rd Annual Evercore ISI HealthCONx Conference

  • November 10, 2020 | Press Releases

    Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study

  • November 5, 2020 | Press Releases

    Rallybio to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

  • November 2, 2020 | Press Releases

    Rallybio Appoints Paula Soteropoulos to Board of Directors

  • September 11, 2020 | Press Releases

    Rallybio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

More from the Newsroom

Rallybio

234 Church Street
Suite 1020
New Haven, CT 06510

203-859-3820

  • Rallybio on Linkedin
  • Rallybio Newsroom

© 2021 Rallybio

  • |Terms of Use
  • |Privacy Policy